Novartis saw its shares rise after positive Phase 3 trial data for its multiple sclerosis drug remibrutinib, while GSK advanced its mRNA flu vaccine into late-stage testing. Conversely, Alumis experienced a steep 54% stock drop following a missed midstage lupus trial endpoint, and Arsenal Biosciences cut 99 jobs as it restructured around in vivo CAR-T therapies. Meanwhile, Roche secured a pipeline deal worth up to $1.53 billion for Simcere Zaiming's preclinical trispecific antibody.
01Company specific
Arsenal Biosciences Cuts Majority of Staff in Pivot to In Vivo CAR-T
Abandoning ex vivo cell manufacturing for in vivo delivery trades high clinical development capital for direct competition with big pharma's established targeted platform pipelines.
Arsenal Biosciences is laying off 99 employees, representing the majority of its staff, as it abandons ex vivo clinical development to focus on in vivo CAR-T therapies. The biotech previously cut half its workforce in September 2025, leaving it with 127 workers before this latest round. All development of existing ex vivo candidates, including the prior lead asset AB-2100, has stopped as the company shifts its pipeline toward early-stage prostate cancer prospect AB-3028 and preclinical candidate AB-7000. Management is now seeking strategic alternatives for its discarded assets while entering a crowded in vivo cancer field that includes Eli Lilly, Johnson and Johnson, AstraZeneca, and Gilead Sciences subsidiary Kite Pharma. The downsizing follows a $325 million fundraising round two years ago backed by Bristol Myers Squibb and Regeneron.
China Approves Brain-Computer Interface Devices to Challenge Neuralink
Regulatory approval for non-invasive electrode caps gives Chinese BCI developers a faster, lower-risk commercialization pathway than the surgical implants favored by Western competitors.
China's health regulators have granted approvals for a series of brain-technology products, according to scmp.com, as domestic start-ups push to leapfrog Elon Musk's Neuralink. The National Medical Products Administration approved a system developed by Tiankai Suishi (Tianjin) Intelligent Technology on August 19, official records show. The approved device is a cap studded with electrodes that fits over a scalp to read electrical signals given off by the brain. Tiankai Suishi also sells devices that aid early diagnosis of cognitive dysfunction linked to Alzheimer's disease and schizophrenia, and is seeking approval for a depression-diagnosis product. Founded in 2023, the firm has registered of 10.67 million yuan, or US$1.59 million, according to Qichacha. Beijing is offering generous policy support and local governments are providing financing to help Chinese firms compete internationally amidst a rapidly ageing population.
Novartis MS Pill Succeeds in Phase 3 Clinical Trials
Clearing Phase Phase trials without liver toxicity gives remibrutinib a clear safety path to capture market share from competitor BTK inhibitors stalled by safety holds.
Novartis shares rose over 4% on Tuesday after its pill remibrutinib succeeded in a pair of trials for multiple sclerosis. The therapy demonstrated superiority over Sanofi drug Aubagio in cutting yearly relapse rates and inflammatory brain lesions. Unlike rival BTK inhibitors from Merck and Roche, remibrutinib did not trigger the liver-related side effects that have stalled competing programs. Novartis intends to submit the data to health regulators for approval, potentially expanding the drug beyond its current use for chronic skin hives under the brand name Rhapsido. The could unlock over $3 billion in peak annual sales for the company as it seeks to offset losses from patent expirations.
GSK Advances mRNA Flu Vaccine to Phase 3 Testing After Positive Data
Targeting both neuraminidase and hemagglutinin antigens gives GSK a dual-surface mechanism to differentiate its mRNA platform from single-antigen competitors in a shrinking US market.
GSK is advancing its mRNA seasonal flu vaccine candidate into a pivotal this month after reporting superior immune responses in a 971-patient Phase 2 study. The trial tested formulations targeting both hemagglutinin and neuraminidase against standard and high-dose licensed comparators across younger and older adults. This late-stage push aims to revitalize a flu vaccine business that contracted by roughly 25 percent last year under competitive pressure in the United States market. While Moderna secured the first approval for an mRNA flu shot last month with its product mFlusiva, GSK hopes to capture by engaging neuraminidase alongside hemagglutinin for broader protection. The Phase 3 trial will evaluate the optimized B-strain candidate known as FLUm3HA.b-3NA.
Roche Inks Deal Worth Up to $1.53B With Simcere for Trispecific T-Cell Engager
Acquiring Simcere's preclinical asset shows Roche outsourcing early-stage discovery to lock up novel trispecific B-cell depletion mechanisms before clinical proof-of-concept.
Roche is paying Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. The total transaction is valued at up to $1.53 billion, including the upfront fee and tiered royalties of up to double digits on future net sales. Under the agreement, Roche secures exclusive global rights to develop, manufacture, and commercialize the , designated as SIM0660. The molecule is designed to target CD79a, CD19, and CD3 to trigger T cell-mediated killing while limiting cytokine release. This pact marks Roche's second licensing deal in just over a week, following an upfront payment of $190 million for a clinical-stage analog from Hanmi Pharmaceutical.
Attempting to pivot a failed trial into phase three based on interferon gene signature subgroups tests whether regulators will accept post-hoc biomarker stratification to rescue efficacy.
Alumis saw its stock drop 54% to below $10 in premarket trading after its lead TYK2 inhibitor, envudeucitinib, missed both primary and secondary endpoints in a phase 2b lupus trial named Lumus. The study tested three oral doses of the drug against a placebo across 408 adults with systemic lupus erythematosus over 48 weeks. Despite the trial failure, CEO Martin Babler and Chief Medical Officer Jörn Drappa announced plans to advance the drug into by focusing on a prespecified subgroup of patients with a high interferon gene signature. In this high-signature subgroup, which made up about 60% of trial participants, the top dose of envudeucitinib achieved a 52.6% response rate compared to 24.4% in low-signature patients. Management intends to discuss these subgroup findings with the to design a phase 3 study that restricts enrollment to high-signature patients or limits low-signature participants. Alumis is also preparing to submit the molecule for approval in psoriasis following a phase 3 trial win earlier in the year.
Lumus Trial Response Rate by Subgroup (%)
High interferon patients showed double the response rate of low-signature peers.
Novocure Discloses Cyberattack Exposing U.S. Patient Records
Medical device makers escape the worst valuation penalties of healthcare data breaches as long as core therapy delivery systems and operational safety remain demonstrably uncompromised.
Novocure disclosed a cybersecurity incident in a September 1 SEC filing that exposed the internal records of more than 1,400 U.S. patients. The breach occurred in mid-August when unauthorized actors accessed certain information systems at the company. The compromised data included internal patient ID numbers, employee job titles and phone numbers, and contact details for healthcare providers. A separate group of fewer than 50 patients in the western U.S. had additional identifying information exposed. Novocure stated that its medical treatment devices remained uncompromised and operational. The company does not expect the incident to materially affect its financial condition.
Pharmaceutical pipelines are delivering mixed clinical results alongside heavy dealmaking and restructuring. What is unresolved is whether Arsenal's drastic pivot to in vivo CAR-T and Alumis's subgroup strategy for its failed lupus drug will ultimately pay off for investors.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.